In terms of p-ERK inhibition, our data are commensurate with previous reports wherein a reduction in ERK phosphorylation was observed in response to NFV in multiple myeloma [15,85], HER2-positive and -negative breast cancer cells [13], medullary thyroid cancer [86], and adenoid cystic carcinoma [87]. Here, ERBB2 is linked to plasma cell myeloma.